Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : New Phase III data support the -2-

09/20/2021 | 09:05am EDT

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] Lee JM, et al. Real-World Adjuvant Treatment Patterns and Survival Outcomes Among Early NSCLC US Patients [ESMO 2021 Abstract #1600]

[2] Felip E, et al. IMpower010: Sites of Relapse and Subsequent Therapy From a Phase 3 Study of Atezolizumab vs Best Supportive Care After Adjuvant Chemotherapy in Resected Stage IB-IIIA NSCLC [ESMO 2021 Abstract #LBA9].

[3] Altorki N, et al. IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab [WCLC 2021 Abstract #PL02.05].

[4] World Health Organization: GLOBOCAN 2020 -- Lung Cancer: Estimated cancer incidence, mortality and prevalence worldwide. [Internet; cited September 2021] Available from: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

[5] American Cancer Society: What Is Lung Cancer? [Internet; cited September 2021] Available from: https://www.cancer.org/cancer/lung-cancer/about/what-is.html

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: media.relations@roche.com https://www.globenewswire.com/Tracker?data=uiNnFFDfEobOfWX6OmXDqR9po64SFLQI49uvoTIOx3zdCsSCg_wmkVVddRHoHtCUjTNBIBOibXxvsBotcy6x9XXMEESkqAz0NhfKzqERL8oW0dZwNg7OV2_8Gm9NWRUs

 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: +41 61 687 05 17     Phone: +41 61 688 44 86 
Dr. Barbara von Schnurbein  Karsten Kleine 
 Phone: +41 61 687 89 67     Phone: +41 61 682 28 31 
Nina Mählitz           Nathalie Meetz 
 Phone: +41 79 327 54 74     Phone: +41 61 687 43 05 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: +41 61 68-78503                        Phone: +41 61 68-83894 
 e-mail: mailto:karl.mahler@roche.com          e-mail: jon_kaspar.bayard@roche.com 
 karl.mahler@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: +41 61 68-88027                        Phone: +41 61 68-75284 
 e-mail: mailto:sabine.borngraeber@roche.com   e-mail: bruno.eschli@roche.com 
 sabine.borngraeber@roche.com 
--------------------------------------------  -------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: +41 61 68-84814                        Phone: +41 61 68-72942 
 e-mail: mailto:birgit.masjost@roche.com       e-mail: mailto:gerard.tobin@roche.com 
 birgit.masjost@roche.com                      gerard.tobin@roche.com 
--------------------------------------------  -------------------------------------- 
 
Investor Relations North America 
Loren Kalm 
 Phone: +1 650 225 3217 
 e-mail: mailto:kalm.loren@gene.com 
 kalm.loren@gene.com 
-------------------------------------------- 
 

Attachment

   -- 20092021_MR_IMpower010_en 
      https://ml-eu.globenewswire.com/Resource/Download/6f62d570-cbbc-4a6e-b038-7f32460eb566 
 
 
 

(END) Dow Jones Newswires

September 20, 2021 09:05 ET (13:05 GMT)

All news about ROCHE HOLDING AG
07:17aCHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Services
AQ
07:17aROCHE : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Third Quarter Sal..
AQ
05:01aROCHE HOLDINGS AG : JP Morgan sticks Neutral
MD
02:50aROCHE HOLDINGS AG : Credit Suisse reiterates its Neutral rating
MD
10/20ROCHE HOLDINGS AG : Bernstein reiterates its Buy rating
MD
10/20ROCHE HOLDINGS AG : Goldman Sachs reiterates its Buy rating
MD
10/20ROCHE HOLDINGS AG : Barclays gives a Buy rating
MD
10/20ROCHE HOLDINGS AG : Gets a Neutral rating from Kepler Cheuvreux
MD
10/20ROCHE HOLDINGS AG : Gets a Neutral rating from UBS
MD
10/20OLEG DERIPASKA : Stocks Drift as -2-
DJ
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 027 M 67 520 M 67 520 M
Net income 2021 14 749 M 16 056 M 16 056 M
Net cash 2021 4 505 M 4 904 M 4 904 M
P/E ratio 2021 20,3x
Yield 2021 2,62%
Capitalization 312 B 339 B 339 B
EV / Sales 2021 4,95x
EV / Sales 2022 4,80x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 357,80 CHF
Average target price 383,40 CHF
Spread / Average Target 7,16%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG13.98%333 101
JOHNSON & JOHNSON4.07%431 148
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952
MERCK & CO., INC.-0.89%205 219